SCHEMBL4246045

SCHEMBL4246045

COC(=O)/C(C#N)=C\c1ccccc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCL1 Q07820 1/20 0.62
ALDH1A1 P00352 4/20 0.59
KDM4E B2RXH2 4/20 0.59
MAPT P10636 1/20 0.59
KMT2A Q03164 1/20 0.59
TDP1 Q9NUW8 1/20 0.59
L3MBTL1 Q9Y468 1/20 0.59
POLB P06746 2/20 0.57
LMNA P02545 2/20 0.55
PLIN1 O60240 1/20 0.55
PLIN5 Q00G26 1/20 0.55
ABHD5 Q8WTS1 1/20 0.55
ADORA2A P29274 1/20 0.55
ADORA2B P29275 1/20 0.55
ADORA1 P30542 1/20 0.55
GAA P10253 1/20 0.52
HPGD P15428 1/20 0.52
ATM Q13315 1/20 0.51
APP P05067 1/20 0.51
SNCA P37840 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6927070 1.00 MCL1 (0.62) MCL1ALDH1A1KDM4EMAPTKMT2A
SCHEMBL4246049 1.00 MCL1 (0.62) MCL1ALDH1A1KDM4EMAPTKMT2A
SCHEMBL10413552 0.91 KDM4E (0.59) ALDH1A1KDM4EMAPTKMT2ATDP1
SCHEMBL10413551 0.91 KDM4E (0.59) ALDH1A1KDM4EMAPTKMT2ATDP1
SCHEMBL16534385 0.87 IDE (0.56) ALDH1A1KDM4EMAPTKMT2ATDP1
SCHEMBL16534387 0.87 IDE (0.56) ALDH1A1KDM4EMAPTKMT2ATDP1
SCHEMBL21457683 0.85 LMNA (0.64) ALDH1A1KDM4EMAPTKMT2ATDP1
SCHEMBL21457684 0.85 LMNA (0.64) ALDH1A1KDM4EMAPTKMT2ATDP1
SCHEMBL7110181 0.85 ALDH1A1 (0.54) ALDH1A1KDM4EMAPTKMT2ATDP1
SCHEMBL14413763 0.85 ALDH1A1 (0.54) ALDH1A1KDM4EMAPTKMT2ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115515685-B EIF4E inhibitors and uses thereof 皮克医疗公司 2025-04-08 CN disclosed
US-12157731-B2 EIF4E inhibitors and uses thereof PIC Therapeutics, Inc. (US) 2024-12-03 US disclosed
US-20230399322-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-12-14 US disclosed
US-20230399322-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-12-14 US disclosed
US-20230399322-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-12-14 US disclosed
US-11753403-B2 EIF4E inhibitors and uses thereof PIC Therapeutics, Inc. (US) 2023-09-12 US disclosed
US-11753403-B2 EIF4E inhibitors and uses thereof PIC Therapeutics, Inc. (US) 2023-09-12 US disclosed
US-11753403-B2 EIF4E inhibitors and uses thereof PIC Therapeutics, Inc. (US) 2023-09-12 US disclosed
EP-4114529-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. (US) 2023-01-11 EP disclosed
CN-115515685-A EIF4E inhibitor and application thereof 皮克医疗公司 2022-12-23 CN disclosed
US-20220356178-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2022-11-10 US disclosed
WO-2021178488-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. (US) 2021-09-10 WO disclosed
WO-2021178488-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. (US) 2021-09-10 WO disclosed
US-20170305754-A1 MANUFACTURING METHOD OF MESOPOROUS INORGANIC OXIDE AND MESOPOROUS INORGANIC OXIDE MADE BY THE SAME INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIVERSITY (KR) 2017-10-26 US disclosed
US-20090203694-A1 INHIBITORS OF UNDECAPRENYL PYROPHOSPHATE SYNTHASE HURLEY TIMOTHY BRIAN 2009-08-13 US disclosed
US-20090203694-A1 INHIBITORS OF UNDECAPRENYL PYROPHOSPHATE SYNTHASE HURLEY TIMOTHY BRIAN 2009-08-13 US disclosed
US-20090203694-A1 INHIBITORS OF UNDECAPRENYL PYROPHOSPHATE SYNTHASE HURLEY TIMOTHY BRIAN 2009-08-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230399322-A1 EIF4E INHIBITORS AND USES THEREOF EIF4E, EIF4EBP1, EIF4A1 MCL1 1262/4885ALDH1A1 4776/4885KDM4E 710/4885
US-12157731-B2 EIF4E inhibitors and uses thereof EIF4E, EIF4EBP1, EIF4A1 MCL1 1262/4885ALDH1A1 4776/4885KDM4E 710/4885
US-20090203694-A1 INHIBITORS OF UNDECAPRENYL PYROPHOSPHATE SYNTHASE FDPS, UMPS, GGPS1 MCL1 3863/4885ALDH1A1 3119/4885KDM4E 3718/4885
US-11753403-B2 EIF4E inhibitors and uses thereof EIF4E, EIF4EBP1, EIF4A1 MCL1 1262/4885ALDH1A1 4776/4885KDM4E 710/4885
US-20220356178-A1 EIF4E INHIBITORS AND USES THEREOF EIF4E, EIF4EBP1, EIF4A1 MCL1 1262/4885ALDH1A1 4776/4885KDM4E 710/4885
US-20170305754-A1 MANUFACTURING METHOD OF MESOPOROUS INORGANIC OXIDE AND MESOPOROUS INORGANIC OXIDE MADE BY THE SAME SAMM50, MACO1, CA7 MCL1 3007/4885ALDH1A1 4221/4885KDM4E 1879/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.